In their excellent review of neuropsychiatric problems in Parkinson's disease (PD), 1 the authors made one small error but more importantly raised an interesting question about drug trials. Also, as they wrote their article, both melperone (personal communication) and pimavanserin, 2 subjected to ra
Reply: Neuropsychiatric symptoms in Parkinson's disease
β Scribed by D. Aarsland; L. Marsh; A. Schrag
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 51 KB
- Volume
- 26
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Neuropsychiatric symptoms are common in Parkinson's disease, even at the earliest stages, and have important consequences for quality of life and daily functioning, are associated with increased carer burden and increased risk for nursing home admission. In addition to cognitive impairm
## Abstract A crossβsectional study of the profile of psychiatric symptoms and their relationships to medications, executive performance, and excessive daytime somnolence (EDS) was conducted on 1351 consecutive Parkinson's disease patients without dementia (PDβND). Ratings were: neuropsychiatric in
## Abstract Visual symptoms are common in PD and PD dementia and include difficulty reading, double vision, illusions, feelings of presence and passage, and complex visual hallucinations. Despite the established prognostic implications of complex visual hallucinations, the interaction between cogni
## Abstract Although diagnosed by characteristic motor features, Parkinson's disease may be preceded, and is frequently accompanied by, a wide range of cognitive and neuropsychiatric features. In addition to the most commonly studied disorders of dementia, depression, and psychosis, other relativel
We appreciate the careful reading of our manuscript by Okun and colleagues. 1 However, their letter contains a number of inaccuracies that require correction. We clearly state